Business
Cardax Welcomes Cardiovascular Research Breakthrough
Cardax Welcomes Cardiovascular Research Breakthrough.
About this update from Cardax Inc
[{"type":"text","content":"\n\n\n\nCardax Welcomes Cardiovascular Research Breakthrough\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnsbls{\nBORDER-LEFT:black 1pt solid\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n.prnsbbs{\nBORDER-BOTTOM:black 1pt solid\n}\n.prnvab{\nVERTICAL-ALIGN: BOTTOM\n}\n.prnrbrs{\nBORDER-RIGHT:black 1pt solid\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbts{\nBORDER-TOP:black 1pt solid\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntblns{\nBORDER-TOP: 1pt; BORDER-RIGHT: 1pt; BORDER-COLLAPSE: collapse; BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt\n}\n\n\n\n\n\n\nCardax Welcomes Cardiovascular Research Breakthrough\nRole of Inflammation in Cardiovascular Health Validated\nPR Newswire\nHONOLULU, Sept. 19, 2017\n\n\n\nHONOLULU, Sept. 19, 2017 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) welcomes the findings of a clinical study recently published in the New England Journal of Medicine that validate the crucial role inflammation plays in cardiovascular health. The 10,000 patient, double-blind, placebo-controlled study (\"CANTOS\") sponsored by Novartis demonstrated, for the first time in history, that an anti‑inflammatory drug reduced major adverse cardiovascular events—independent of cholesterol levels.\n\nThe study supports the opportunity Cardax sees for its astaxanthin supplement ZanthoSyn® to manage cardiovascular inflammatory health with substantial safety and cost benefits compared to the agent used in this study.\n\nWhile this study does not prove that other anti-inflammatory approaches will have similar benefits in cardiovascular health, cardiovascular experts not involved in the trial have pointed to the broad potential application of this study to support the use of other anti-inflammatory agents.\n\nFor example, Cleveland Clinic's heart chief, Dr. Steven Nissen, was quoted by the Washington Post as saying, \"It (this study) opens up an entirely new vista for the treatment of heart disease, because now everybody on the planet—in the pharmaceutical industry and in research institutions like ours and at the National Institutes of Health—are going to be looking to find an...